BIO vs NBY · rev $651.0M vs $51.9M cap
BIO (BIO) versus NovaBay Pharmaceuticals Inc (NBY) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
NovaBay Pharmaceuticals Inc (NBY) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
NBY does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. NBY currently screens at market cap $51.9M.
Not investment advice. Open the BIO and NBY stock pages for the full models.
Not investment advice.